Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Exelixis stock
Learn how to easily invest in Exelixis stock.
Exelixis Inc (EXEL) is a leading biotechnology business based in the US. It opened the day at $15.99 after a previous close of $15.89. During the day the price has varied from a low of $15.68 to a high of $16.22. The latest price was $15.90 (25 minute delay). Exelixis is listed on the NASDAQ and employs 954 staff. All prices are listed in US Dollars.
How to buy shares in Exelixis
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – EXEL – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Exelixis stock price (NASDAQ: EXEL)Use our graph to track the performance of EXEL stocks over time.
Exelixis shares at a glance
|52-week range||$15.50 - $23.40|
|50-day moving average||$19.27|
|200-day moving average||$19.77|
|Wall St. target price||$27.46|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$0.84|
Buy Exelixis shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Exelixis stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Exelixis price performance over time
|1 week (2022-09-21)||-3.64%|
|1 month (2022-08-26)||-12.78%|
|3 months (2022-06-28)||-24.07%|
|6 months (2022-03-24)||N/A|
|1 year (2021-09-27)||-23.19%|
|2 years (2020-09-28)||-33.00%|
|3 years (2019-09-27)||17.995|
|5 years (2017-09-28)||24.23|
Is Exelixis stock undervalued or overvalued?
Valuing Exelixis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Exelixis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Exelixis's P/E ratio
Exelixis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 19x. In other words, Exelixis shares trade at around 19x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Exelixis's PEG ratio
Exelixis's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.3259. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Exelixis's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Exelixis's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $351.2 million.
The EBITDA is a measure of a Exelixis's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$1.6 billion|
|Operating margin TTM||21.56%|
|Gross profit TTM||$1.4 billion|
|Return on assets TTM||7.98%|
|Return on equity TTM||12.3%|
|Market capitalisation||$5.2 billion|
TTM: trailing 12 months
Exelixis share dividends
We're not expecting Exelixis to pay a dividend over the next 12 months.
Exelixis share price volatility
Over the last 12 months, Exelixis's shares have ranged in value from as little as $15.5 up to $23.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Exelixis's is 0.6484. This would suggest that Exelixis's shares are less volatile than average (for this exchange).
Exelixis, Inc. , an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc.
Exelixis in the news
2 No-Brainer Biotech Stocks to Buy Right Now
3 Monster Stocks in the Making
3 Biotech Stocks to Buy Now for Extraordinary Gains
Frequently asked questionsWhat percentage of Exelixis is owned by insiders or institutions?
Currently 2.159% of Exelixis shares are held by insiders and 89.91% by institutions. How many people work for Exelixis?
Latest data suggests 954 work at Exelixis. When does the fiscal year end for Exelixis?
Exelixis's fiscal year ends in January. Where is Exelixis based?
Exelixis's address is: 1851 Harbor Bay Parkway, Alameda, CA, United States, 94502 What is Exelixis's ISIN number?
Exelixis's international securities identification number is: US30161Q1040 What is Exelixis's CUSIP number?
Exelixis's Committee on Uniform Securities Identification Procedures number is: 30161Q104
More guides on Finder
How to buy YanGuFang International Group (YGF) stock when it goes public
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
How to buy Lead Real Estate Co. (LRE) stock when it goes public
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
How to buy Third Harmonic Bio (THRD) stock
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
How to buy LINKBANCORP (LNKB) stock
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
Ask an Expert